Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
about
Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment ConsiderationsAngiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancerHormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium studyTissue-specific pathways for estrogen regulation of ovarian cancer growth and metastasisPrognostic value of progesterone receptor expression in ovarian cancer: a meta-analysisGauging NOTCH1 Activation in Cancer Using Immunohistochemistry.Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortiumSUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance.Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer.Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment.Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers.Correlation between estrogen receptor expression and prognosis in epithelial ovarian cancer: a meta-analysis.Population prevalence of familial cancer and common hereditary cancer syndromes. The 2005 California Health Interview Survey.Hormone receptors expression in ovarian cancer taking into account menopausal status: a retrospective study in Chinese population.The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
P2860
Q26751021-B29D9EA2-9626-487C-9138-9F17AC06FC7AQ28732124-55B2DE3E-421E-4FFB-A1A4-67803A57DE57Q33551425-F9CB0722-CF06-479F-86DC-1EDEF4C63E9CQ33722942-444F5FA7-DDF6-4F50-9962-E33A4C073F31Q33829679-D38BBC89-08D9-4CB9-AE60-9AA43B7CD420Q34794876-359C3564-7AB2-49FE-AC4A-BC10F945E98AQ35209384-F753525C-2B40-42AD-96DE-CB868C6E385BQ35510378-6C6C70EC-98A9-4A66-A1DC-DCB954724444Q35897417-2CF1C69C-80DC-4866-A420-9BE28C4C3F21Q36498614-6D46A77D-0D73-4113-970D-2913E890F4AAQ37426775-C732F3D8-495F-408B-8C7D-8877D8695678Q38616195-DB5B96A1-7495-4058-B5AF-115B329B4653Q38787442-8315148B-C58E-4346-AEFB-AA4163B19CA1Q39219310-BFC78FDF-119D-436A-9FFF-FAE586E9BCBDQ42365343-C8897BDB-511D-42C7-94AB-883FC3923CB4Q44181640-486182C1-3753-4915-A891-EDCF7DD1962BQ47119695-BBBE0095-D9DE-444C-8453-C75223D1F3D9Q47132013-BA84AF8C-E8AD-4EA1-8E95-F0BA1035134CQ47771135-730CDCF6-8074-45A7-8419-0D743961530D
P2860
Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prognosis and hormone receptor ...... lary serous ovarian carcinoma.
@en
Prognosis and hormone receptor ...... lary serous ovarian carcinoma.
@nl
type
label
Prognosis and hormone receptor ...... lary serous ovarian carcinoma.
@en
Prognosis and hormone receptor ...... lary serous ovarian carcinoma.
@nl
prefLabel
Prognosis and hormone receptor ...... lary serous ovarian carcinoma.
@en
Prognosis and hormone receptor ...... lary serous ovarian carcinoma.
@nl
P2093
P1433
P1476
Prognosis and hormone receptor ...... lary serous ovarian carcinoma.
@en
P2093
Joyce F Liu
Michelle S Hirsch
Ursula A Matulonis
P304
P356
10.1016/J.YGYNO.2009.08.023
P407
P577
2009-09-30T00:00:00Z